Revance Therapeutics (NASDAQ:RVNC) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Revance Therapeutics (NASDAQ:RVNC) in a research report released on Thursday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

Several other research analysts also recently issued reports on RVNC. HC Wainwright reiterated a “neutral” rating and set a $6.60 price target on shares of Revance Therapeutics in a research report on Friday, November 8th. Mizuho decreased their price target on shares of Revance Therapeutics from $6.66 to $3.10 and set a “neutral” rating on the stock in a research note on Tuesday, December 10th. Barclays reissued an “equal weight” rating and issued a $7.00 price target (down previously from $10.00) on shares of Revance Therapeutics in a report on Friday, September 13th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Revance Therapeutics in a report on Friday, November 8th. Nine analysts have rated the stock with a hold rating and one has given a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $8.96.

Revance Therapeutics Trading Down 0.3 %

NASDAQ:RVNC opened at $3.08 on Thursday. The stock has a market capitalization of $323.09 million, a P/E ratio of -1.60 and a beta of 0.81. Revance Therapeutics has a 1 year low of $2.30 and a 1 year high of $9.74. The firm has a 50 day moving average of $4.56 and a 200-day moving average of $4.46.

Revance Therapeutics (NASDAQ:RVNC) last issued its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.02). The business had revenue of $59.88 million during the quarter, compared to analysts’ expectations of $67.73 million. As a group, analysts forecast that Revance Therapeutics will post -1.57 EPS for the current fiscal year.

Institutional Trading of Revance Therapeutics

A number of institutional investors have recently bought and sold shares of the business. Certuity LLC acquired a new position in shares of Revance Therapeutics in the 2nd quarter valued at $26,000. Vanguard Personalized Indexing Management LLC bought a new stake in Revance Therapeutics in the second quarter valued at about $33,000. Hsbc Holdings PLC acquired a new position in Revance Therapeutics in the second quarter valued at about $38,000. Nisa Investment Advisors LLC boosted its holdings in Revance Therapeutics by 2,167.5% during the second quarter. Nisa Investment Advisors LLC now owns 18,911 shares of the biopharmaceutical company’s stock worth $49,000 after buying an additional 18,077 shares during the last quarter. Finally, FORA Capital LLC acquired a new position in shares of Revance Therapeutics during the 3rd quarter worth about $54,000. Institutional investors and hedge funds own 97.70% of the company’s stock.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.